Tags

Type your tag names separated by a space and hit enter

Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells.
Leuk Lymphoma 2018; 59(1):196-203LL

Abstract

Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs. However, the relationship between angiogenesis and JAK2 V617F and the effects of ruxolitinib on angiogenesis are still unknown. Here, we observed the correlation of JAK2 V617F mutation burden with VEGF, HIF-1a and microvascular density (MVD) in MPNs. We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1α in JAK2 V617F positive cells. We found the expression levels of p-JAK2, VEGF, HIF-1a and MVD in the newly diagnosed MPNs were significantly increased and were related to the JAK2 V617F burden. Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels' formation in chick embryo choriallantoic membrane. Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells.

Authors+Show Affiliations

a Department of Hematology , The No. 1 Hospital of Baoding , Baoding , China.a Department of Hematology , The No. 1 Hospital of Baoding , Baoding , China.a Department of Hematology , The No. 1 Hospital of Baoding , Baoding , China.a Department of Hematology , The No. 1 Hospital of Baoding , Baoding , China.a Department of Hematology , The No. 1 Hospital of Baoding , Baoding , China.b Department of Hematology , Hebei General Hospital , Shijiazhuang , Hebei Province , China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28554272

Citation

Cheng, Zhiyong, et al. "Angiogenesis in JAK2 V617F Positive Myeloproliferative Neoplasms and Ruxolitinib Decrease VEGF, HIF-1 Enesis in JAK2 V617F Positive Cells." Leukemia & Lymphoma, vol. 59, no. 1, 2018, pp. 196-203.
Cheng Z, Fu J, Liu G, et al. Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. Leuk Lymphoma. 2018;59(1):196-203.
Cheng, Z., Fu, J., Liu, G., Zhang, L., Xu, Q., & Wang, S. Y. (2018). Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. Leukemia & Lymphoma, 59(1), pp. 196-203. doi:10.1080/10428194.2017.1324155.
Cheng Z, et al. Angiogenesis in JAK2 V617F Positive Myeloproliferative Neoplasms and Ruxolitinib Decrease VEGF, HIF-1 Enesis in JAK2 V617F Positive Cells. Leuk Lymphoma. 2018;59(1):196-203. PubMed PMID: 28554272.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells. AU - Cheng,Zhiyong, AU - Fu,Jianzhu, AU - Liu,Guimin, AU - Zhang,Lijun, AU - Xu,Qian, AU - Wang,Su-Yun, Y1 - 2017/05/30/ PY - 2017/5/31/pubmed PY - 2018/8/1/medline PY - 2017/5/31/entrez KW - HIF-1α KW - JAK2 V617F mutation KW - Myeloproliterative neoplasms KW - VEGF KW - angiogenesis KW - ruxolitinib SP - 196 EP - 203 JF - Leukemia & lymphoma JO - Leuk. Lymphoma VL - 59 IS - 1 N2 - Angiogenesis and JAK2 V617F mutation are common in BCR-ABL1 negative myeloproliferative neoplasms (MPNs). Ruxolitinib, a JAK inhibitor, is an effective treatment for some MPNs. However, the relationship between angiogenesis and JAK2 V617F and the effects of ruxolitinib on angiogenesis are still unknown. Here, we observed the correlation of JAK2 V617F mutation burden with VEGF, HIF-1a and microvascular density (MVD) in MPNs. We investigate the effect of ruxolitinib on the expression of VEGF and HIF-1α in JAK2 V617F positive cells. We found the expression levels of p-JAK2, VEGF, HIF-1a and MVD in the newly diagnosed MPNs were significantly increased and were related to the JAK2 V617F burden. Ruxolitinib can inhibit p-JAK2, VEGF, HIF-1a expression and suppress blood vessels' formation in chick embryo choriallantoic membrane. Our findings indicated that angiogenesis is related to JAK2 V617F burden and ruxolitinib could decrease VEGF and HIF-1a expression in JAK2 V617F positive cells. SN - 1029-2403 UR - https://www.unboundmedicine.com/medline/citation/28554272/Angiogenesis_in_JAK2_V617F_positive_myeloproliferative_neoplasms_and_ruxolitinib_decrease_VEGF_HIF_1_enesis_in_JAK2_V617F_positive_cells_ L2 - http://www.tandfonline.com/doi/full/10.1080/10428194.2017.1324155 DB - PRIME DP - Unbound Medicine ER -